The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

Novavax Swings to Profit in Q4 2025 as Sales Surge; Shares Rally

Key Facts

1Novavax swung to a profit in the fourth quarter of 2025 as sales climbed.

2Novavax (NVAX) shares rose following the announcement of its quarterly and full-year financial results.

Novavax Inc. (NVAX) reported a significant financial turnaround in its fourth-quarter 2025 results, shifting from previous losses to a net profit. The biotechnology firm's return to profitability was primarily driven by a substantial climb in sales revenue during the reporting period, exceeding previous performance metrics. Following the release of the quarterly and full-year financial data, shares of Novavax experienced an immediate upward trajectory in the market. This positive performance marks a critical milestone for the company as it strengthens its balance sheet and operational efficiency. Investors responded favorably to the news, viewing the sales growth as a strong catalyst for the company's long-term outlook in the pharmaceutical sector. The report highlights Novavax's successful efforts to stabilize its operations and capitalize on its product pipeline.